Delivery Order SPE2DB24D2101-SPE2DB25FKPDL
- Not listed
- This is a $2,465.76 firm-fixed price delivery order awarded to Amerisourcebergen Drug Corp's Corporate Office Division by the Defense Logistics Agency (DLA) Troop Support Medical for the supply of Neulasta OnPro 6 mg/0.6 ml kits. The order is part of Amerisourcebergen's larger $999,999,999.00 Indefinite Delivery Contract with DLA to provide a comprehensive range of pharmaceutical products and medical supplies to support the Department of Defense's global military treatment programs and...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $17,831.39, is for the delivery of NEULASTA ONPRO 6 MG/0.6 ML KIT 0.6ML, a specialty medication. This contract does not have a set-aside designation, indicating it was competed openly. AmerisourceBergen is the prime contractor, and the contract has an ultimate completion date of...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $27,729.49, is for the supply of Neulasta OnPro 6 mg/0.6 ml kits to support federal healthcare programs, particularly military and veterans' healthcare systems. The contract has an ultimate completion date of February 4, 2025. AmerisourceBergen holds a significant Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $12,549.14 to AmerisourceBergen Drug Corp for the supply of Neupogen 300 mcg/ml vials. The contract, awarded on August 18, 2025, with an ultimate completion date of August 19, 2025, utilizes firm fixed pricing with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under the company's broader...
- The Defense Logistics Agency awarded a delivery order valued at $2,528.36 to AmerisourceBergen Drug Corp for the supply of Nivestym 300 mcg/mL vials. This non-competitive, firm fixed-price delivery order, awarded on September 2, 2025, represents a continuation of pharmaceutical procurement under DLA's medical supply chain operations. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 3, 2025....
- The Defense Logistics Agency awarded a delivery order valued at $1,934.37 to AmerisourceBergen Drug Corp for the supply of Neupogen 480 mcg/1.6 mL vials on July 28, 2025. This is a firm fixed-price delivery order with an ultimate completion date of July 29, 2025, with performance to be executed from the contractor's Conshohocken, Pennsylvania facility. The contract includes no set-aside designation, indicating it was awarded through open competition. Neupogen (filgrastim) is a critical...
- The Defense Logistics Agency awarded a delivery order valued at $1,929.20 to AmerisourceBergen Drug Corp for Nemluvio 30 mg pens, with an ultimate completion date of September 19, 2025. This competitive award, which utilized firm fixed pricing with no set-aside designation, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be performed at the contractor's facility in Conshohocken,...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp for the supply of NEUPOGEN 480 MCG/0.8 ML SYR 0.8ML, a specialty pharmaceutical product. The contract has a firm fixed price of $17,160.11 and a period of performance through November 14, 2024. Amerisourcebergen is a major pharmaceutical distribution and healthcare solutions provider, and this contract is part of the company's broader Indefinite Delivery Contract (IDC) with the DLA...
- The Defense Logistics Agency awarded a $9,646 delivery order to AmerisourceBergen Drug Corp for the supply of Nemluvio 30 mg pens, with an ultimate completion date of August 15, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal...
- The Defense Logistics Agency awarded a delivery order valued at $3,858.40 to AmerisourceBergen Drug Corp for the supply of Nemluvio 30 mg pens under contract 4569086102. This firm fixed price delivery order, issued on August 13, 2025, is part of a larger indefinite delivery contract (IDC) vehicle and represents a competitive award with no set-aside designation. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, with an ultimate completion date of September...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKPDLDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,438.72 to AmerisourceBergen Drug Corp for Neulasta 6 mg/0.6 ml syringes on September 3, 2025, with an ultimate completion date of September 4, 2025. This competitively awarded, firm fixed-price delivery order represents a pharmaceutical supply transaction supporting federal medical procurement needs. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with no set-aside designation applied. This delivery order is a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This prime IDC serves as a comprehensive pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of brand-name and generic medications, vaccines, and medical supplies to support military healthcare programs globally. The delivery order for Neulasta, a pharmaceutical treatment used in oncology and hematology care, exemplifies the vendor's role in fulfilling critical medical supply requirements for Defense Health Agency and related military healthcare systems through the DLA's established pharmaceutical distribution framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.4k | 9/3/25 |